◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Gland Pharma Limited (GLAND)
公式財務諸表に基づく売上高、利益、キャッシュフローの推移。
Healthcare · ウォール街（米国） · 最終更新: 2026-09-20
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules.
主要指標
- 時価総額: ₹489 billion
- 売上高（2026-03-31 期末の会計年度）: ₹64.0B
- 当期純利益: ₹10.3B
- 売上総利益率: 65.0%
- 純利益率: 16.0%
インタラクティブチャートと全財務諸表を見る →
年次損益計算書
| 損益計算書 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|
| 売上高合計 | ₹64.0B | ₹55.8B | ₹56.4B | ₹35.9B |
| 売上総利益 | ₹41.6B | ₹34.9B | ₹34.7B | ₹19.1B |
| 営業利益（EBIT） | ₹12.1B | ₹8.9B | ₹10.0B | ₹8.7B |
| 当期純利益 | ₹10.3B | ₹7.0B | ₹7.7B | ₹7.8B |
出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。
貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は GLAND のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/GLAND
類似企業
本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.